Aviva’s Arcturus Therapeutics ARCT Stock Holding History

Aviva’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-24,093	Closed	-$760K	–	963
2023 Q4	$760K	Buy	+24,093	New	+$573K	﹤0.01%	716

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Aviva's ARCT Position: Q1 2024 in Review

Aviva sold out of Arcturus Therapeutics (ARCT) in Q1 2024, closing a stake of 24,093 shares — an estimated $760K sold.

Aviva first reported a position in ARCT in Q4 2023 and held it in 1 quarter. The position peaked at $760K in Q4 2023. 179 funds tracked by Wall St. Rank hold ARCT as of Q1 2024.

Aviva reported no remaining Arcturus Therapeutics position as of Q1 2024 after selling out during the quarter.
Aviva sold 24,093 Arcturus Therapeutics shares in Q1 2024, an estimated $760K.
Aviva first reported a position in Arcturus Therapeutics in Q4 2023 and held it in 1 quarter.
Aviva's Arcturus Therapeutics position peaked at $760K in Q4 2023.
179 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2024.

Based on Aviva's 13F filing for Q1 2024, filed 14 May 2024.